Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis - Cochrane Hepato-Biliary Group

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 11-12, 2006, Pages 1535-1544

  Gong, Y ^a   Klingenberg, S L ^a   Gluud, C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PENICILLAMINE; PLACEBO;

AGEUSIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASCITES; ASTHMA; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GOODPASTURE SYNDROME; HEART PALPITATION; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERSENSITIVITY; IMMUNOMODULATION; JAUNDICE; LEUKOPENIA; LICHEN PLANUS; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; META ANALYSIS; MORTALITY; MYASTHENIA; NEUTROPENIA; OUTCOME ASSESSMENT; PEMPHIGOID; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPLENOMEGALY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

CHELATING AGENTS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PENICILLAMINE; RANDOMIZED CONTROLLED TRIALS;

EID: 33845499048     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03164.x     Document Type: Review

References (30)

1. rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. Community. Gatroenterology 2000; 119: 1631-6.
2. Sherlock S, Heathcote J. Primary biliary cirrhosis. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford: University Press, 1999: 1089-98.
3. Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995; 22: 1158-62.
4. Nimni ME, Deshmukh K, Gerth N. Collagen defect induced by d-penicillamine. Nature 1972; 240: 220-1.
5. Epstein O, De Villiers D, Jain S, et al. Reduction of immune complexes and immunoglobulins induced by d-penicillamine in primary biliary cirrhosis. N Engl J Med 1979; 300: 274-8.
6. Lipsky PE, Ziff M. Inhibition of human helper t cell function in vitro by d-penicillamine and copper sulfate. J Clin Invest 1980; 65: 1069-76.
7. Triger DR, Manifold IH, Cloke P, Underwood JCE. D-penicillamine in primary biliary cirrhosis: two year results of a single centre, double-blind controlled trial. Gut 1980; 21: A919-20.
8. Epstein O, Jain S, Lee RG, et al. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1981; 1: 1275-7.
9. Taal BG, Schalm SW, Ten Kate FWJ, Henegouwen GPB, Brandt KH. Low therapeutic value of d-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver 1983; 3: 345-52.
10. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. Eur J Gastroenterol Hepatol 1999; 11: 817-20.
11. Gong Y, Frederiksen SL, Gluud C. D-penicillamine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004; Issue 4. Art. No.:CD004789.
12. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
13. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
14. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
15. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. In: 1997 CFR & ICH Guidelines. USA: Barnett International/PAREXEL, 1997: 1-71.
16. Gamble C, Hollis S. Uncertainty method improved on best/worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005; 58: 579-88.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
18. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 341-50.
19. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
20. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
21. Bassendine MF, Macklon AF, Mulcahy R, James OFW. Controlled trial of high and low dose d-penicillamine (dp) in primary biliary cirrhosis (pbc): results at three years (abstract). Gut 1982; 23: A909.
22. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of d-penicillamine in primary biliary cirrhosis. N Engl J Med 1982; 306: 319-26.
23. Dickson ER, Fleming TR, Wiesner RH, et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985; 312: 1011-5.
24. Neuberger J, Christensen E, Portmann B, et al. Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985; 26: 114-9.
25. Bodenheimer HC, Schaffner F, Sternlieb I, et al. A prospective clinical trial of d-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985; 5: 1139-42.
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
27. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997; 315: 629-34.
28. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A 2001; 98: 831-6.
29. Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gatroenterology 2002; 123: 1044-51.
30. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examing heterogeneity and combing results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context, 2nd edn. London: BMJ Books, 2001: 285-312.